Navigation Links
Conseco Files to Formally Extend Due Date for Annual Report on Form 10-K to March 17 and Reschedules Earnings Release and Investor Call
Date:3/4/2008

CARMEL, Ind., March 4 /PRNewswire-FirstCall/ -- In a filing with the SEC yesterday, Conseco, Inc. (NYSE: CNO), formally extended the due date of its Annual Report on Form 10-K to March 17, 2008. In the Form 12b-25 filing, the Company said it has not yet finalized its December 31, 2007 financial statements and is completing several items, including its analysis to determine the possible need to increase the deferred income tax asset valuation allowance. Conseco estimated that its net income (loss) for the three months ended December 31, 2007 will be approximately breakeven, including estimated net realized investment losses (after related amortization and taxes) of $25 million, but before any adjustments which may result from finalizing the incomplete items.

The Company also reported in its Form 12b-25 filing that it has been consulting with the staff of the SEC's Office of the Chief Accountant (the "SEC Staff") regarding its accounting policy for long-term care premium rate increases as described in the Summary of Significant Accounting Policies in its 2006 Form 10-K. On February 28, 2008, the SEC Staff informed Conseco of their view that the use of a method which prospectively changes reserve assumptions for long-term care policies based solely on changes in premium rates is not consistent with the guidance of Statement of Financial Accounting Standards No. 60, "Accounting and Reporting by Insurance Enterprises." The Company is continuing to evaluate the SEC Staff's view and has reflected the estimated effect in the estimated net income (loss) provided above.

As a result of these developments, the Company will report results for the fourth quarter of 2007 before the market opens on Monday, March 17 and will host its quarterly call with investors at 1:00pm EDT that day. Both events have been delayed from dates the Company announced in a press release on Feb. 25, 2008.

About Conseco

Conseco, Inc.'s insurance companies help protect working American families and seniors from financial adversity: Medicare supplement, long-term care, cancer, heart/stroke and accident policies protect people against major unplanned expenses; annuities and life insurance products help people plan for their financial futures. For more information, visit Conseco's web site at http://www.conseco.com.

Cautionary Statement Regarding Forward-Looking Statements. Our statements, trend analyses and other information contained in this press release relative to markets for Conseco's products and trends in Conseco's operations or financial results, as well as other statements, contain forward- looking statements within the meaning of the federal securities laws and the Private Securities Litigation Reform Act of 1995. Forward-looking statements typically are identified by the use of terms such as "anticipate," "believe," "plan," "estimate," "expect," "project," "intend," "may," "will," "would," "contemplate," "possible," "attempt," "seek," "should," "could," "goal," "target," "on track," "comfortable with," "optimistic" and similar words, although some forward-looking statements are expressed differently. You should consider statements that contain these words carefully because they describe our expectations, plans, strategies and goals and our beliefs concerning future business conditions, our results of operations, financial position, and our business outlook or they state other "forward-looking" information based on currently available information. Assumptions and other important factors that could cause our actual results to differ materially from those anticipated in our forward-looking statements include, among other things: (i) our ability to obtain adequate and timely rate increases on our supplemental health products including our long-term care business; (ii) mortality, morbidity, usage of health care services, persistency, the adequacy of our previous reserve estimates and other factors which may affect the profitability of our insurance products; (iii) changes in our assumptions related to the cost of policies produced or the value of policies inforce at the Effective Date; (iv) our ability to achieve anticipated expense reductions and levels of operational efficiencies including improvements in claims adjudication and continued automation and rationalization of operating systems; (v) performance of our investments; (vi) our ability to identify products and markets in which we can compete effectively against competitors with greater market share, higher ratings, greater financial resources and stronger brand recognition; (vii) the ultimate outcome of lawsuits filed against us and other legal and regulatory proceedings to which we are subject; (viii) our ability to remediate the material weakness in internal controls over the actuarial reporting process that we identified at year-end 2006 and to maintain effective controls over financial reporting; (ix) our ability to continue to recruit and retain productive agents and distribution partners and customer response to new products, distribution channels and marketing initiatives; (x) our ability to achieve an upgrade of the financial strength ratings of our insurance company subsidiaries as well as the potential impact of rating downgrades on our business; (xi) the risk factors or uncertainties listed from time to time in our filings with the Securities and Exchange Commission; (xii) regulatory changes or actions, including those relating to regulation of the financial affairs of our insurance companies, such as the payment of dividends to us, regulation of financial services affecting (among other things) bank sales and underwriting of insurance products, regulation of the sale, underwriting and pricing of products, and health care regulation affecting health insurance products; (xiii) general economic conditions and other factors, including prevailing interest rate levels, stock and credit market performance and health care inflation, which may affect (among other things) our ability to sell products and access capital on acceptable terms, the returns on and the market value of our investments, and the lapse rate and profitability of policies; and (xiv) changes in the Federal income tax laws and regulations which may affect or eliminate the relative tax advantages of some of our products.

Other factors and assumptions not identified above are also relevant to the forward-looking statements, and if they prove incorrect, could also cause actual results to differ materially from those projected. All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by the foregoing cautionary statement. Our forward-looking statements speak only as of the date made. We assume no obligation to update or to publicly announce the results of any revisions to any of the forward- looking statements to reflect actual results, future events or developments, changes in assumptions or changes in other factors affecting the forward- looking statements.


'/>"/>
SOURCE Conseco, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Hacker Joins Conseco as Senior Vice President and Treasurer
2. Tongson Joins Conseco as Senior Vice President, Corporate Actuarial
3. Conseco to Implement Systems and Operational Solution From Long Term Care Group
4. Conseco Reports Third Quarter Results
5. Conseco Sets Earnings Release Date
6. Conseco Completes Divestiture of Old Block of Fixed and Equity-Indexed Annuities
7. Barta joins Conseco as Senior Vice President, Financial Planning & Analysis; Barra named Senior Vice President, Internal Audit; Clarke to head Investor Relations
8. Conseco to Host Follow-Up Long-Term Care Conference Call
9. RealSelf.com Denies Lifestyle Lifts Trademark Claims and Files Countersuit
10. Novo Nordisk Files Annual Report with the SEC
11. PLC Systems Files IDE Supplement to Begin Pivotal Study of RenalGuard(TM) and Provides Update on Planned Development Timeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... , ... "Success Files," a short- and long-form documentary style ... disease estimated to affect the lives of more than 5 million Americans living ... leading voice in the fight for cure and research into the disease, its ...
(Date:9/22/2017)... ... 2017 , ... Egg freezing and embryo freezing are both ... slight statistical advantage for live births, frozen eggs offer many advantages, depending on ... medical treatment or who are concerned about the decline of their fertility as ...
(Date:9/21/2017)... ... 2017 , ... SABRE is raising awareness about personal safety with a Chicago ... November. , The Chicago, Illinois, based self-defense brand has been waiting for an opportunity ... of taking their personal safety into their own hands. , The ads focus on ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... Bill Howe ... to its customers, and give back to the community. For over 37 years, they ... most successful companies serving plumbing in San Diego. They were chosen as ...
(Date:9/21/2017)... ... September 21, 2017 , ... Japanese Zen artist couple, ... Revolution” on 6th, 7th and 8th October at Miranda Kuo Gallery on Lower East ... pieces, such as Zen Kodo mat. Wanderlust , one of the largest US ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... -- Eli Lilly and Company (NYSE: LLY ... galcanezumab and lasmiditan, two investigational treatments for migraine, at ... taking place Sept. 7-10 in Vancouver ... data from an open-label study evaluating the safety and ... 240 mg) for the prevention of migraine. Galcanezumab is ...
(Date:9/5/2017)... JERUSALEM , Sept. 5, 2017 Oramed Pharmaceuticals ... www.oramed.com ), a clinical-stage pharmaceutical company focused on the ... it has successfully concluded its meeting with the U.S. ... novel oral insulin formulation. ... that the regulatory pathway for submission of ORMD-0801, would ...
(Date:8/29/2017)... 29, 2017 ivWatch, LLC, the leading provider of continuous ... it has been awarded an Innovative Technology contract from Vizient, Inc., ... ... aid in the early detection of peripheral IV infiltration and extravasation ... The Innovative Technology contract was awarded ...
Breaking Medicine Technology: